Lupin Ramps Up Strategy to Counter U.S. Tariff Threat, Posts 52% Profit Surge
Mumbai, August 7, 2025 — Indian pharmaceutical giant Lupin is drawing up a multi-pronged strategy to navigate the looming threat of U.S. tariffs, while celebrating a robust 52% year-on-year surge…
Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug
Hyderabad: In a ray of hope for HIV patients, particularly for the significant burden in the two-Telugu speaking States of Telangana and Andhra Pradesh, several India pharmaceutical companies have secured…
Indian generic drugs linked to deaths in US? Trade group slams study blaming desi pharma
A study linking Indian-made generic drugs to a higher risk of serious side effects in the US has drawn backlash from the industry’s most influential lobby group, as India moves…
US Tariffs on pharma: What are the potential impact on Indian drugmakers
US tariffs on pharmaceutical imports by the US President Donald Trump have sparked concerns within India’s pharma sector, a global leader in affordable generic drug supplies. In an exclusive interaction…